Article
Gastroenterology & Hepatology
Christopher Ma, Stephen E. Congly, Kerri L. Novak, Paul J. Belletrutti, Maitreyi Raman, Matthew Woo, Christopher N. Andrews, Yasmin Nasser
Summary: The management of chronic symptomatic functional bowel disorders (FBDs) in the United States incurs considerable healthcare resource use and cost, with pharmacologic therapies being more commonly prescribed than nonpharmacologic interventions. Combination treatment strategies are more likely to be implemented by primary care physicians, highlighting the need to improve comprehensive FBD management.
Review
Oncology
Brian H. Le, Ghauri Aggarwal, Carol Douglas, Michael Green, Amanda Nicoll, Sam Ahmedzai
Summary: This study highlights the efficacy of naloxone in combination with oxycodone for preventing opioid-induced constipation, as well as the potential risks in patients with unrecognized liver impairment. It suggests that clinicians should consider the presence of hepatic impairment when unexpected outcomes occur with the combination of oxycodone and naloxone, even if liver function test results are normal.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Environmental Sciences
Enrico Polati, Marta Nizzero, Jacopo Rama, Alvise Martini, Leonardo Gottin, Katia Donadello, Giovanna Del Balzo, Giustino Varrassi, Franco Marinangeli, Alessandro Vittori, Erica Secchettin, Vittorio Schweiger
Summary: This retrospective study demonstrates that long-term opioid treatment with a combination of oxycodone and naloxone can significantly hinder the development of opioid tolerance in patients with chronic low back pain. Additionally, it confirms the positive effect of naloxone in reducing opioid-induced bowel dysfunction incidence.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Neurosciences
Jie Liu, Chaolan Lv, Wei Wang, Yizhou Huang, Bo Wang, Jiashuang Tian, Chenyu Sun, Yue Yu
Summary: This study found that a 6-week slow, deep breathing (SDB) intervention improved symptoms and altered rectal sensation in constipation-predominant IBS (IBS-C) patients. Additionally, SDB enhanced vagal activity, suggesting that the effect of SDB on IBS-C may be due to mechanisms involving autonomic responses.
FRONTIERS IN NEUROSCIENCE
(2022)
Article
Cell Biology
Yemin Wan, Dan Zhang, Ting Xing, Qiaoling Liu, Yumeng Chi, Huixiang Zhang, Haihua Qian
Summary: Obesity has become a concern in patients with inflammatory bowel disease (IBD), particularly related to chronic constipation, inflammation, immune function and cognition. This study of 150 IBD patients found a high prevalence of visceral obesity, with a significant impact on chronic constipation, inflammation levels, and immune function in those with Crohn's disease.
Article
Neurosciences
Grace J. Lee, Shin Ae Kim, Yea Jin Kim, Seog Bae Oh
Summary: The analgesic effect induced by naloxone may be mediated by blocking facilitated kappa-opioid systems in the NAc and CeA, while KOR antagonist also reduces chronic pain behaviors.
Article
Multidisciplinary Sciences
Scott G. Weiner, Michelle A. Hendricks, Sanae El Ibrahimi, Grant A. Ritter, Sara E. Hallvik, Christi Hildebran, Roger D. Weiss, Edward W. Boyer, Diana P. Flores, Lewis S. Nelson, Peter W. Kreiner, Michael A. Fischer
Summary: This study examined the risks of chronic use and overdose associated with hydrocodone and oxycodone in opioid-naive patients following their initial prescription. The results showed that hydrocodone had a slightly higher risk of chronic use, while oxycodone, especially when used in monotherapy, posed a higher risk of overdose. This suggests that hydrocodone may be a preferable choice to reduce overdose-related deaths.
Article
Anesthesiology
Stijn Veldman, Maria van Beek, Steffie van Rijswijk, Hannah Ellerbroek, Hans Timmerman, Selina van der Wal, Monique Steegers, Arnt Schellekens
Summary: This study investigated the added value of buprenorphine or naloxone (BuNa) in patients with chronic noncancer pain (CNCP) and opioid use disorder (OUD). The results showed that conversion to BuNa led to decreased self-reported pain, increased pain thresholds and tolerance, and improved quality of life (QoL) in these patients.
Article
Biochemistry & Molecular Biology
Jordi Barrachina, Cesar Margarit, Javier Muriel, Vicente Lopez-Gil, Santiago Lopez-Gil, Pura Ballester, Laura Mira-Lorente, Laura Agullo, Ana M. Peiro
Summary: Despite a large amount of research on sex differences in pain, this study found that there is a lack of translation to real-world pain management. The study analyzed sex differences in the response to different opioids among patients with chronic non-cancer pain. The results showed that there were sex differences in drug tolerability and hospital resources, with females experiencing lower tolerability and higher hospital use, particularly in the group using oxycodone/naloxone. Other differences related to age and prescription of benzodiazepines were also found.
Review
Medicine, General & Internal
Mia Schmidt-Hansen, Michael Bennett, Stephanie Arnold, Nathan Bromham, Jennifer S. Hilgart, Andrew J. Page, Yuan Chi
Summary: The study assessed the effectiveness and tolerability of oxycodone compared to other analgesic options for cancer pain relief in adults, finding little to no difference between oxycodone and other strong opioids including morphine in terms of pain intensity, pain relief, and adverse events.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2022)
Article
Health Care Sciences & Services
Montserrat Vinas-Bastart, Miriam Oms-Arias, Africa Pedraza-Gutierrez, Irene Lizano-Diez, Eduardo L. Marino, Pilar Modamio
Summary: This study aimed to characterize the use of tapentadol and oxycodone/naloxone in primary health care, identifying similarities in their use patterns and patient profiles. Regular assessment of prescribing practices and monitoring is recommended to ensure patient safety and effective pain management.
RISK MANAGEMENT AND HEALTHCARE POLICY
(2021)
Article
Substance Abuse
Fares Qeadan, Erin Fanning Madden
Summary: The study found that receiving a naloxone prescription was associated with an increased risk of subsequent opioid overdose among patients with acute and chronic pain, suggesting that prescribers often identify patients most in need of naloxone.
Article
Gastroenterology & Hepatology
Sameer K. Berry, Rani Berry, David Recker, Jeffrey Botbyl, Lucy Pun, William D. Chey
Summary: Digital gut-directed hypnotherapy (GDH) treatment program can improve symptoms of IBS, including abdominal pain and stool problems. There was no significant difference in effectiveness between digital GDH and digital muscle relaxation (MR), but the GDH treatment group had more abdominal pain responders.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Vikram Rangan, Prashant Singh, Sarah Ballou, Rafla Hassan, Vanessa Yu, Jesse Katon, Judy Nee, Johanna Iturrino, Anthony Lembo
Summary: Improvement in constipation and diarrhea were found to predict improvement in abdominal pain in patients with functional bowel disorders, highlighting the importance of addressing these factors in the management of abdominal pain in these conditions.
NEUROGASTROENTEROLOGY AND MOTILITY
(2022)
Article
Geriatrics & Gerontology
Ulderico Freo, Maurizio Furnari, Francesco Ambrosio, Paolo Navalesi
Summary: The study indicates that tapentadol extended release maintains efficacy and good tolerability in elderly patients with chronic low back pain, providing significant pain relief, and improving quality of life and sleep.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2021)